NR5A2 is mainly expressed in the pancreas and liver, making it an attractive target for selectively inhibiting SOX2 in pancreatic ductal adenocarcinoma (PDAC). This evidence concerns the gene SOX2 and pancreatic ductal adenocarcinoma.